ImmuCell Q1 sales, profit rise on seasonal demand; to moderate mid-year

ImmuCell

14/05/2026 21:19

Overview

US animal health biologics firm's Q1 product sales grew 28% yr/yr, driven by seasonal demand

Q1 net income rose to $1.9 mln, with gross margin expanding to 45%

Company settled disputes with former contract manufacturer, receiving $2 mln for capacity expansion

Outlook

Company expects revenue to moderate mid-year after peak seasonal demand

ImmuCell plans significant First Defense capacity expansion

Company will continue to invest in commercial execution and manufacturing yield improvement

Result Drivers

SEASONAL DEMAND & MARKET SHARE - Record revenue driven by high seasonal demand from cow-calf segment and increased market share in U.S. scours biologicals market, per SVP Bobbi Brockmann

MARGIN EXPANSION - Gross margin rose to 45% due to higher volumes, manufacturing efficiencies, and price realization, according to CFO Timothy C. Fiori

INCREASED PRODUCTION - Average monthly output rose to over 450,000 units, up from 380,000 in 2025, due to yield improvements at existing plant, per CEO Olivier te Boekhorst

Company press release: ID:nGNX4R5dMB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
$0.21
Q1 Net Income
$1.94 mln
Q1 Operating Expenses
$2.69 mln
Q1 Pretax Profit
$1.95 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)